Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Charité Universitätsmedizin Berlin, Campus Charité Mitte, Berlin.
J Dtsch Dermatol Ges. 2010 Jan;8(1):65-6. doi: 10.1111/j.1610-0387.2009.07312_supp.x.
In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.
2009 年 2 月，欧洲药品管理局（EMEA）人用医药产品委员会（CHMP）建议暂停依氟鸟氨酸（Raptiva）的上市许可，因为其在治疗银屑病方面的益处有限，而接受该药治疗的患者存在严重副作用的风险，包括进行性多灶性白质脑病（PML）的发生。指导小组已相应地修改了指南。
